



# MEDICO REMEDIES LTD.

A WHO-GMP, ISO 9001-2015 & GOVT. RECOGNISED STAR EXPORT HOUSE

Manufacturers of Pharmaceutical Formulations



CIN : L24230MH1994PLC077187  
GSTIN- 27AABCM8349L1ZY

Regd. Office : 1105/1106, Hubtown Solaris, N. S. Phadke Marg, Opp. Teligali, Andheri - East, Mumbai - 400 069. • Tel. : +91-22-2682 1054 / 1055 / 2683 7116  
Email : medicoremedies@yahoo.com • info@medicoremedies.com • Website : www.medicoremediesindia.com • www.medicoremediesindia.net • www.tabletandcapsules.com

**Date: 5<sup>th</sup> February, 2025**

<b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001 <b>Scrip Code: 540937</b>	<b>National Stock Exchange of India Limited</b> 5 <sup>th</sup> Floor, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai-400051 <b>Symbol: MEDICO</b>
---	--

Dear Sir/Madam,

**Re.: Integrated Filing (Financials)**

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31<sup>st</sup> December, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2<sup>nd</sup> January, 2025, we are submitting herewith the Integrated Filing (Financials) for the quarter and nine-months ended 31<sup>st</sup> December, 2024.

Kindly take the same on record.

Thanking You,

**FOR MEDICO REMEDIES LIMITED**

**HARESH MEHTA**  
**CHAIRMAN & WHOLE-TIME DIRECTOR**  
**DIN: 01080289**

*Encl: As above*

## A. FINANCIALS



**V J SHAH & CO**  
CHARTERED ACCOUNTANTS

4th Floor, 'K' Building, 24, Walchand Hirachand Marg,  
Ballard Estate, Near GPO, CST, Mumbai 400001 India  
• 022 40966263 • 022 22666363  
• info@vjshahco.com • www.vjshahco.com

**Independent Auditor's Limited Review Report on Quarterly Unaudited Standalone Financial Results of Medico Remedies Limited pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015, as amended**

**To**  
**THE BOARD OF DIRECTORS**  
**MEDICO REMEDIES LIMITED**

We have reviewed the accompanying Statement of unaudited Standalone Financial Results of Medico Remedies Limited ("the Company") for the quarter ended 31<sup>st</sup> December, 2024 together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015 ("the Regulation") as amended (the "Listing Regulations").

This Statement which is the responsibility of the Company's Management has been reviewed by Audit Committee and approved by the Board of Directors at their respective meetings held on 05<sup>th</sup> February, 2025 has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (IND AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedure applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Standalone Financial Results prepared in accordance with applicable Indian Accounting Standard specified





**V J SHAH & CO**  
CHARTERED ACCOUNTANTS

under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

UDIN: 25164370BMIEJE6011

**For V J SHAH & CO,**  
**Chartered Accountants**  
**Firm Registration No.: 109823W**

*Chintan V Shah*

**CHINTAN V SHAH**  
**Partner**  
**Membership Number - 164370**



**Place: Mumbai**  
**Date: 05.02.2025**

**MEDICO REMEDIES LIMITED**  
CIN: L24230MH1994PLC077187  
**Statement of Unaudited Standalone Financial Results for the Period Ended Dec 31, 2024**

(Rs. in lakhs)

Sn	Particulars	Quarter ended			For the Period Ended		For the Year Ended
		31-Dec-24 (Unaudited)	30-Sep-24 (Unaudited)	31-Dec-23 (Unaudited)	31-Dec-24 (Unaudited)	31-Dec-23 (Unaudited)	31-Mar-24 (Audited)
1	<b>Income</b>						
	(a) Revenue from Operations	3,948.99	3,934.94	2,977.22	10,963.74	10,359.79	14,492.07
	(b) Other Income	142.50	67.82	27.28	239.64	154.42	212.85
	<b>Total Income (a+b)</b>	<b>4,091.49</b>	<b>4,002.76</b>	<b>3,004.50</b>	<b>11,203.38</b>	<b>10,514.21</b>	<b>14,704.91</b>
2	<b>Expenses</b>						
	(a) Cost of raw materials consumed	3,092.90	2,849.14	2,425.97	8,197.38	7,644.88	10,609.89
	(b) Purchase of traded goods	33.39	68.11	50.28	153.83	106.05	177.07
	(c) Changes in inventories of finished goods, work-in progress and traded goods	-260.14	107.59	-320.76	-254.69	200.73	203.70
	(d) Employee Benefits Expense	187.58	137.74	172.03	469.50	455.66	592.03
	(e) Finance Costs	27.62	21.18	22.25	66.45	57.64	82.35
	(f) Depreciation and Amortisation Expense	76.41	74.82	71.97	226.45	214.15	287.94
	(g) Other Expenses	583.95	530.97	376.47	1,563.94	1,126.11	1,618.44
	<b>Total expenses</b>	<b>3,741.70</b>	<b>3,789.55</b>	<b>2,798.21</b>	<b>10,422.86</b>	<b>9,805.22</b>	<b>13,571.42</b>
3	<b>Profit/(Loss) before Tax (1-2)</b>	<b>349.79</b>	<b>213.21</b>	<b>206.29</b>	<b>780.52</b>	<b>708.99</b>	<b>1,133.49</b>
4	<b>Income Tax expenses</b>						
	a) Current Tax	79.14	60.00	66.76	192.54	197.42	316.64
	b) Deferred Tax [(charge)/(credit)]	8.68	-2.17	-5.00	12.74	-7.61	-12.24
	<b>Total Tax Expenses</b>	<b>87.82</b>	<b>57.83</b>	<b>61.76</b>	<b>205.28</b>	<b>189.81</b>	<b>304.40</b>
5	<b>Profit/(Loss) for the period (3-4)</b>	<b>261.97</b>	<b>155.38</b>	<b>144.53</b>	<b>575.24</b>	<b>519.18</b>	<b>829.09</b>
6	Other comprehensive income not to be reclassified to Profit and Loss in subsequent periods						
	Profit and Loss in subsequent periods						
	Re-measurement gain/(losses) on defined benefit Plans	0.30	0.30	0.84	0.90	2.52	31.68
	Tax effect [(charge)/credit]	-0.07	-0.08	-0.21	-0.23	-0.63	-7.97
	Other comprehensive income/(loss) (net of tax)	0.23	0.22	0.63	0.67	1.89	23.70
7	<b>Total comprehensive income/(loss) for the period (5+6)</b>	<b>262.19</b>	<b>155.60</b>	<b>145.16</b>	<b>575.91</b>	<b>521.07</b>	<b>852.80</b>
8	Paid-up equity share capital(Face value per share: Re.2/-) (No.in lakhs)	829.84	829.84	829.84	829.84	829.84	829.84
9	Other Equity excluding revaluation reserve as per the audited balance sheet						3,577.42
10	Earning per Equity Share of face value of Re.2/- each (Not Annualised)						
	Basic EPS (in Rs.)	0.32	0.19	0.17	0.69	0.63	1.00
	Diluted EPS (in Rs.)	0.32	0.19	0.17	0.69	0.63	1.00

For Medico Remedies Limited

*Haresh Mehta*

**Haresh Mehta**  
Chairman and Whole Time Director  
DIN:01080289  
Place: Mumbai  
Date: February 05, 2025

*Harshit Mehta*

**Harshit Mehta**  
Managing Director  
DIN:05144280  
Place: Mumbai  
Date: February 05, 2025



**Notes:**

1. The above unaudited standalone financial results of the company were reviewed and recommended by the audit committee on February 05, 2025 and subsequently approved by the Board of Directors at its meeting held on February 05, 2025. The review report has been filed with stock exchange and is available on the Company's website.
2. The figures for the quarter ended on 31<sup>st</sup> December, 2024 are balancing figures between the reviewed figures for the quarter ended 30<sup>th</sup> September 2024 and reviewed year to date figures upto nine month ended 31<sup>st</sup> December, 2024.
3. The standalone financial results for the quarter ended on 31<sup>st</sup> December, 2024 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued unmodified report on unaudited financial results.
4. The above financial results have been prepared as per IND AS and all standards and requirements of IND AS are complied with by the company.
5. Medico Remedies Limited is a pharmaceutical formulation manufacturing company and the management reviews the performance of the company as a single operating segment in accordance with IND-AS 108 "Operating Segments" notified pursuant to Companies (Accounting Standard) Rules, 2015. Accordingly, no segment information/segment reporting has been furnished within. Details of geographical segments are disclosed below:

PARTICULARS		QE 31.12.2024	QE 30.09.2024
		Amount (Rs. In Lakh)	Amount (Rs. In Lakh)
1)	Sales of products within India	71.47	244.40
2)	Sales of products Outside India	3842.90	3655.85
	<b>Total</b>	<b>3914.37</b>	<b>3900.25</b>

6. Previous periods figures have been regrouped / reclassified where required to make them compatible with the figures of current periods.
7. The company does not have any subsidiary/associate/joint venture company as on December 31, 2024
8. The results for the quarter ended December 31,2024 is available on the BSE Limited website (URL: [www.bseindia.com](http://www.bseindia.com)), NSE Limited website (URL: [www.nseindia.com](http://www.nseindia.com)) and on the Company's website (URL: [www.medicoremedies.com](http://www.medicoremedies.com))

**For and on behalf of the board,  
For Medico Remedies Limited**

**Haresh Mehta**  
**Chairman and Whole Time Director**  
**DIN:01080289**  
Place: Mumbai  
Date: February 05, 2025

**Harshit Mehta**  
**Managing Director**  
**DIN:05144280**  
Place: Mumbai  
Date: February 05, 2025





# MEDICO REMEDIES LTD.

A WHO-GMP, ISO 9001-2015 & GOVT. RECOGNISED STAR EXPORT HOUSE

Manufacturers of Pharmaceutical Formulations



CIN : L24230MH1994PLC077187  
GSTIN- 27AABCM8349L1ZY.

---

Regd. Office : 1105/1106, Hubtown Solaris, N. S. Phadke Marg, Opp. Teligali, Andheri - East, Mumbai - 400 069. • Tel. : +91-22-2682 1054 / 1055 / 2683 7116  
Email : medicoremedies@yahoo.com • info@medicoremedies.com • Website : www.medicoremediesindia.com • www.medicoremediesindia.net • www.tabletandcapsules.com

---

**B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. - Not Applicable**

**C. Format for disclosing outstanding default on Loans and Debt securities - Not Applicable**

**D. Format for disclosure of Related Party Transactions - Not Applicable for this quarter**

**E. Statement on Impact of Audit Qualifications (For Audit Report with Modified Opinion) submitted along-with Annual Audited Financial Results - Not Applicable for this quarter**